[{"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "577.36", "Date_of_Payment": "10/04/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24448900", "Name_of_Associated_Covered_Drug_or_Biological1": "JANUVIA", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "395.46", "Date_of_Payment": "08/09/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24446207", "Name_of_Associated_Covered_Drug_or_Biological1": "JANUVIA", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "377.59", "Date_of_Payment": "12/20/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24448863", "Name_of_Associated_Covered_Drug_or_Biological1": "JANUVIA", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "265.00", "Date_of_Payment": "11/14/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24448862", "Name_of_Associated_Covered_Drug_or_Biological1": "JANUVIA", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "182.52", "Date_of_Payment": "09/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24446206", "Name_of_Associated_Covered_Drug_or_Biological1": "JANUVIA", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "211123", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "ELI LILLY AND COMPANY", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "52.00", "Date_of_Payment": "12/31/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "105731344", "Name_of_Associated_Covered_Drug_or_Biological1": "AXIRON", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Randomized Double Blind Placebo Controlled Parallel Study With an Open Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone Sex Drive and Energy in Hypogonadal Men", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01816295", "Context_of_Research": ""}]